News
BLPH
1.050
+3.45%
0.035
Bellerophon Therapeutics GAAP EPS of -$0.53 beats by $0.05
Seekingalpha · 11/14 14:07
BRIEF-Bellerophon Provides Clinical Program Update And Reports Third Quarter 2022 Financial Results
Reuters · 11/14 13:40
Bellerophon Therapeutics Q3 EPS $(0.53) Down From $(0.49) YoY
Benzinga · 11/14 13:35
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
Gainers
Benzinga · 09/28 09:10
Nasdaq Turns Higher; Crude Oil Rises Over 2%
U.S. stocks pared some losses toward the end of trading, with the Nasdaq Composite turning higher on Tuesday.
Benzinga · 09/27 18:58
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers
Benzinga · 09/27 17:39
US Stocks Turn Lower; Dow Dips 175 Points
U.S. stocks turned lower midway through trading, with the Dow Jones dropping around 175 points on Tuesday.
Benzinga · 09/27 16:41
Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
Gainers
Benzinga · 09/27 16:23
Why Are Bellerophon Shares Jumping Today?
Benzinga · 09/27 16:07
Bellerophon stock gains ~24% after getting FDA nod to reduce phase 3 study size
Bellerophon Therapeutics (NASDAQ:BLPH) on Tuesday ...
Seekingalpha · 09/27 15:40
BRIEF-Bellerophon Announces FDA Acceptance Of Change To Ongoing Phase 3 Rebuild Study Of Inopulse
BRIEF-Bellerophon Announces FDA Acceptance Of Change To Ongoing Phase 3 Rebuild Study Of Inopulse
Reuters · 09/27 13:21
Bellerophon Announces FDA Acceptance Of Change To Ongoing Phase 3 REBUILD Study Of INOpulse For Treatment Of Fibrotic Interstitial Lung Disease
New study size of 140 patients for the REBUILD Study, without modifying trial objective or endpoints and maintaining power of >90% for the primary endpoint   Independent Data Monitoring Committee agreed
Benzinga · 09/27 12:32
Bellerophon Therapeutics' New Phase 3 Trial Size for Lung Disorder Drug Gets US FDA Nod; Shares Rise
Bellerophon Therapeutics' New Phase 3 Trial Size for Lung Disorder Drug Gets US FDA Nod; Shares Rise
MT Newswires · 09/27 11:19
AEHR, BLPH and CTV among mid-day movers
Gainers: NeuroBo Pharmaceuticals (NRBO) +137%. <li...
Seekingalpha · 09/13 17:21
Bellerophon Therapeutics: Q2 Earnings Insights
  Bellerophon Therapeutics (NASDAQ:BLPH) reported its Q2 earnings results on Monday, August 15, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Bellerophon Therapeutics reported an EPS of $-0.43.
Benzinga · 08/15 13:27
Bellerophon Therapeutics GAAP EPS of -$0.43 beats by $0.17
Bellerophon Therapeutics press release (<span class...
Seekingalpha · 08/15 12:54
BRIEF-Bellerophon Therapeutics reports Q2 results
BRIEF-Bellerophon Therapeutics reports Q2 results
Reuters · 08/15 12:49
Avantor Names Jonathan Peacock Chairman
MT Newswires · 05/13 11:08
Bellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International Conference
WARREN, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced a poster ...
GlobeNewswire · 05/12 12:30
Recap: Bellerophon Therapeutics Q1 Earnings
Bellerophon Therapeutics (NASDAQ:BLPH) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/11 22:34
More
Webull provides a variety of real-time BLPH stock news. You can receive the latest news about Bellerophon Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About BLPH
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The focus of its clinical program is the continued development of its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The Company’s INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical developed for the therapeutic delivery of inhaled nitric oxide. It is also developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD), PH-Sarcoidosis, PH-chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, and other pulmonary hypertension conditions. It has three subsidiaries: Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc.